AzTrials
AzTrials

Hip Fractures (ICD-10 72.01-72.2)NCT07301242

Population Pharmacokinetics and Pharmacodynamics of Ciprofol

An observational study of Hip Fractures (ICD-10 72.01-72.2) and Osteoarthritis, Knee and Hip, run by Shanghai Geriatric Medical Center at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this observational study is to learn how the anesthetic drug ciprofol works in older adults who are having limb surgery under general anesthesia at Shanghai Geriatric Medical Center. Read more about this study

Who is it for?
Ages 65 years and older
What is being tested?
Ciprofol
Type of treatment
Injection or infusion
How many people
50 participants
Where
1 siteChina
Study dates
28 Oct 2025to Dec 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Study population: Elderly patients undergoing orthopedic limb surgery

Who may be able to join

  • Age ≥65 years;
  • BMI: 18-30 kg/m²;
  • ASA physical status classification I-III;
  • Scheduled for elective orthopedic limb surgery under general anesthesia;
  • Expected duration of surgery >30 minutes;
  • Willing to participate and able to provide written informed consent.

Who cannot join

  • Known allergy to ciprofol or related medications, or any contraindication to their use;
  • Preoperative cognitive impairment;
  • History of severe cerebrovascular disease or related complications;
  • History of neuromuscular system diseases or psychiatric disorders;
  • History of sedative medication use;
  • History of alcohol abuse or substance use disorder;
Show all 10Show fewer
  • Bradycardia (heart rate <60 beats per minute);
  • Hypotension (mean arterial pressure <55 mmHg);
  • QT interval prolongation;
  • Uncooperative or unable to communicate effectively.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

China1 site, 1 recruiting
  • Shanghai Geriatric Medical Center

    Shanghai

    Clinical Research Coordinator, 021-64175590, zx02190554@126.com

    Recruiting

Other trials in China

About this study

Official title: Population Pharmacokinetic/Pharmacodynamic Modeling of Ciprofol in Elderly Patients Undergoing Orthopedic Limb Surgery

The goal of this observational study is to learn how the anesthetic drug ciprofol works in older adults who are having limb surgery under general anesthesia at Shanghai Geriatric Medical Center. The study will help researchers build a population model to better understand how the drug moves through the body (PK) and how it affects patients (PD). This model may help doctors use a Target-Controlled Infusion (TCI) system to adjust the drug dose more precisely.

The main question it aims to answer is: Does ciprofol work safely and effectively in older adults during orthopedic surgery?

Read more

Participants already receiving ciprofol as part of their regular anesthesia care will:

  1. Provide blood samples at different time points during and after surgery.
  2. Have their vital signs and anesthesia-related data recorded before, during, and after surgery.
  3. Be monitored for side effects and recovery indicators such as the Aldrete score and signs of postoperative delirium.

Researchers will use this information to:

  1. Build and test a population PK/PD model for ciprofol.
  2. Simulate recommended TCI dosing plans.
  3. Explore how individual responses to ciprofol relate to recovery and safety outcomes.

This study may help improve anesthesia care for elder adults by making drug dosing safer and more effective.

Read the detailed description

Elderly patients undergoing orthopedic limb surgery represent a growing population with unique perioperative challenges. Age-related physiological changes-including reduced hepatic and renal function, altered body composition, and decreased cardiac output-significantly affect the pharmacokinetics (PK) and pharmacodynamics (PD) of anesthetic drugs. These changes increase the difficulty of maintaining adequate anesthesia depth and hemodynamic stability.

Ciprofol, a novel intravenous anesthetic, has shown promising efficacy and safety in clinical practice. However, existing PK/PD models are largely derived from healthy volunteers or younger patients, and cannot adequately predict drug behavior in elderly orthopedic patients who often present with comorbidities and heightened surgical stress. This gap may lead to risks such as drug accumulation and circulatory depression, or insufficient dosing and intraoperative awareness.

This single-center, observational, prospective study at Shanghai Geriatric Medical Center aims to construct and validate a population PK/PD model of ciprofol specifically for elderly patients undergoing orthopedic limb surgery. The model will support precise control of effect-site concentration via Target-Controlled Infusion (TCI) systems, enabling individualized anesthesia management.

Study Objectives 1.Primary Objective: To develop and validate a population PK/PD model of ciprofol tailored to elderly orthopedic patients, and to evaluate its accuracy in predicting effect-site concentrations.

2.Secondary Objectives:

  1. To simulate recommended TCI dosing regimens based on the new model and compare them with current drug label recommendations, assessing clinical value and optimization potential.
  2. To evaluate the anesthetic efficacy and safety of ciprofol in this patient population.

3.Exploratory Objectives: To investigate the influence of covariates (e.g., age, sex, BMI, hepatic and renal function) on PK/PD parameters, and to explore correlations between individual PK/PD parameters and recovery outcomes such as Aldrete score and postoperative delirium incidence.

Study Design

1.Type: Single-center, observational, biosample-utilization study. 2.Population: 45 elderly patients (≥65 years, ASA I-III) scheduled for elective orthopedic limb surgery under general anesthesia.

3.Procedures:

  1. Collection of perioperative clinical data (vital signs, BIS monitoring, anesthesia-related indicators).
  2. Serial blood sampling at predefined time points for plasma concentration measurement.
  3. Monitoring of anesthetic efficacy (induction success, BIS values, recovery times) and safety endpoints (hypotension, bradycardia, hypoxemia, injection pain).

4.Endpoints:

  1. Primary Endpoint: Accuracy of the population PK/PD model in predicting effect-site concentrations.
  2. Secondary Endpoints: Differences between model-recommended dosing and label-based dosing; incidence of ciprofol-related adverse events; anesthetic efficacy indicators.
  3. Exploratory Endpoints: Covariate effects on PK/PD parameters; correlation of PK/PD parameters with Aldrete score recovery and postoperative delirium.

Data Management and Analysis All perioperative data will be recorded and stored electronically, with double-entry verification and query resolution procedures to ensure accuracy. PK/PD modeling will be performed using nonlinear mixed-effects modeling (NONMEM). Model evaluation will include goodness-of-fit plots, visual predictive checks, and bootstrap validation. Simulations will be conducted to compare TCI dosing regimens derived from the new model with standard recommendations.

Expected Significance This study will fill an important gap in anesthetic pharmacology by providing a validated PK/PD model of ciprofol for elderly orthopedic patients. The findings are expected to improve perioperative anesthesia management, enhance patient safety, and support individualized dosing strategies in clinical practice.

Being tested
Ciprofol
Medical subject headings
Hip Fractures, Osteoarthritis, Femoral Neck Fractures

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CiprofolDrug

    Also called Cipepofol, Sishuning

    Ciprofol is used as an intravenous anesthetic agent for sedation and anesthesia induction/maintenance in elderly patients undergoing elective orthopedic limb surgery. In this observational study, ciprofol is administered according to standard clinical practices, and data on its pharmacokinetics, pharmacodynamics, safety, and effectiveness in this specific population will be collected.

Study groups in NCT07301242
Study groupRoleWhat they receive
Elderly Orthopedic Limb Surgery CohortInclusion Criteria: Age ≥65 years; BMI 18-30 kg/m²; ASA physical status classification I-III; Scheduled for elective orthopedic limb surgery under general anesthesia; Expected duration of surgery >30 minutes; Willing to participate and able to provide written informed consent. Exclusion Criteria: Known allergy to ciprofol or related medications, or any contraindication to their use; Preoperative cognitive impairment (Mini-Cog score <3); History of severe cerebrovascular disease or related complications; History of neuromuscular system diseases or psychiatric disorders; History of sedative medication use; History of alcohol abuse or substance use disorder; Bradycardia (heart rate <60 beats per minute); Hypotension (mean arterial pressure <55 mmHg); QT interval prolongation; Uncooperative or unable to communicate effectively.
Receives: Drug: Ciprofol

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Plasma Concentration of Ciprofol

    Arterial or venous blood samples (1 mL each) will be collected to measure the plasma concentration of ciprofol using liquid chromatography - mass spectrometry. These concentration data points will be used to construct the population pharmacokinetic model. Reported in ng/mL.

    Measured: From the start of drug administration to 24 hours after the end of drug administration.

  2. Bispectral Index (BIS) Value

    The BIS value is a non-invasive measure of the level of consciousness/depth of anesthesia, ranging from 0 (isoelectric EEG) to 100 (awake). It is used as the pharmacodynamic metric for modeling.

    Measured: Continuously monitored from the start of anesthesia induction, throughout the maintenance phase, until full recovery (approximately up to 4 hours).

  3. Modified Observer's Assessment of Alertness/Sedation (MOAA/S) Score

    The MOAA/S scale is a categorical measure used to assess the depth of sedation/anesthesia. Scores range from 0 (No response to painful stimulus) to 5 (Responds readily to name spoken in normal tone). This metric will be used as a pharmacodynamic endpoint to construct a categorical PK/PD model (e.g., proportional odds model) relating ciprofol concentration to clinical sedation depth.

    Measured: Induction phase (every minute until loss of consciousness); Maintenance phase; and Post-operative phase (every 3 minutes in PACU until score returns to 5), up to approximately 4 hours.

Secondary outcomes (2)
  1. Mean Arterial Pressure (MAP)

    Evaluation of hemodynamic stability by measuring the absolute value of Mean Arterial Pressure. Reported in millimeters of mercury (mmHg).

    Measured: Continuously measured during the induction, maintenance (intra-operative), and recovery phase (up to 2 hours post-infusion).

  2. Heart Rate

    Evaluation of hemodynamic stability by measuring the absolute value of Heart Rate. Reported in beats per minute (bpm).

    Measured: Continuously measured during the induction, maintenance (intra-operative), and recovery phase (up to 2 hours post-infusion).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Dec 2025
  2. Study start28 Oct 2025
  3. Primary completionNov 2026 (estimated)
  4. Study completionDec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07301242
Sponsor's protocol ID
ZCLY2025-021
Status last verified
Nov 2025
First submitted
19 Nov 2025
Last updated
24 Dec 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Hip Fractures (ICD-10 72.01-72.2) and Osteoarthritis, Knee and Hip, run by Shanghai Geriatric Medical Center at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 24 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Xue Zhang (02164175590, zx02190554@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Plasma Concentration of Ciprofol (time frame: From the start of drug administration to 24 hours after the end of drug administration.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in